Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated
In spite of the increasing number of global health partnerships led by biopharmaceutical companies, there is a paucity of information on the number, type, and role of partners. This paper aims to analyze partnerships carrying out company programs included in Access Accelerated, a new industry initia...
Gespeichert in:
| Veröffentlicht in: | Public health (London) 2020-04, Vol.181, p.73-79 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 79 |
|---|---|
| container_issue | |
| container_start_page | 73 |
| container_title | Public health (London) |
| container_volume | 181 |
| creator | Umeh, C.A. Rockers, P.C. Laing, R.O. Wagh, O. Wirtz, V.J. |
| description | In spite of the increasing number of global health partnerships led by biopharmaceutical companies, there is a paucity of information on the number, type, and role of partners. This paper aims to analyze partnerships carrying out company programs included in Access Accelerated, a new industry initiative, focused on addressing the global non-communicable disease burden.
Document review and content analysis.
We extracted data on the number, type, and role of partners from 63 company programs reported into the Access Observatory, a public platform for reporting on access-to-medicines programs, in 2017. We did a descriptive analysis of the proportion of partners by sector, institution, and location. We used the Fischer’s exact test to analyze the relationship between the program strategies, disease focus, and countries with the type of program partners. Based on our empirical findings, we developed a typology of program partnerships, according to which we categorized each of the 63 programs.
Programs worked with three partners on average, the majority of which were local governmental or non-governmental organizations (70%). Most programs focused on health service strengthening (83%), community awareness and linkage to care (81%), and health service delivery (60%). Twenty-six of the 63 programs (41%) worked with the local Ministries of Health while 25 (40%) partnered with disease-specific organizations, 21 (33%) with hospitals, and 16 (25%) with academic institutions. Partnering with the Ministries of Health was significantly associated with the use of a health service strengthening program strategy (P = 0.02). Partnering with a hospital (P = 0.004) or private sector partner (P = 0.0009) was significantly associated with a program disease focus on cancer. Seventy-nine percent of the programs were solely funded by pharmaceutical companies. According to our program typology, 40 (63%) programs partnered directly or indirectly with multiple implementing organizations, which delivered the program directly to beneficiaries.
Pharmaceutical companies play a leading role in funding Access Accelerated programs with local governmental or non-governmental organizations mainly involved in program implementation. A detailed and transparent reporting of the role of local stakeholders in agenda setting, planning, and coordination of programs is needed to ensure public trust and accountability of programs led by pharmaceutical companies. More research is needed to identify the |
| doi_str_mv | 10.1016/j.puhe.2019.12.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2343037129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0033350619304020</els_id><sourcerecordid>2343037129</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-77f401d5ac3254a2d1fadc8987ff8eade3f976d1f77457f970261f2ced91d9d23</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS1ERaeFF2CBLLFhk9Q_iZ0gNlUFBakSLGBteezrjkeJHey4qA_Rd66HKSxYsLrW1XeOju9B6DUlLSVUXOzbpeygZYSOLWUtIcMztKGdFE0vqHiONoRw3vCeiFN0lvOeEMIk71-gU07HfhCSbdDDt51OszZQVm_0hH2wJa_pvpnA4kWnNUDKO79k7KIpuS5jwNraBDn7cIvXHeDbKW6rdFuShYCjwyGGxsR5LqF6bifA1mfQGfJ7rHGCOw-_DtilMdXl95gg6RXsS3Ti9JTh1dM8Rz8-ffx-9bm5-Xr95erypjF86NZGStcRanttOOs7zSx12pphHKRzA2gL3I1S1K2UXS_rmzBBHTNgR2pHy_g5enf0XVL8WSCvava5pph0gFiyYrzjhEvKxoq-_Qfdx5JCTadYV1NQKntRKXakTIo5J3BqSX7W6V5Rog5lqb06lKUOZSnKVC2rit48WZftDPav5E87FfhwBKDeol4tqWw8hPoPn8Csykb_P_9HtrCoLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2440111756</pqid></control><display><type>article</type><title>Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Elsevier ScienceDirect Journals Collection</source><creator>Umeh, C.A. ; Rockers, P.C. ; Laing, R.O. ; Wagh, O. ; Wirtz, V.J.</creator><creatorcontrib>Umeh, C.A. ; Rockers, P.C. ; Laing, R.O. ; Wagh, O. ; Wirtz, V.J.</creatorcontrib><description>In spite of the increasing number of global health partnerships led by biopharmaceutical companies, there is a paucity of information on the number, type, and role of partners. This paper aims to analyze partnerships carrying out company programs included in Access Accelerated, a new industry initiative, focused on addressing the global non-communicable disease burden.
Document review and content analysis.
We extracted data on the number, type, and role of partners from 63 company programs reported into the Access Observatory, a public platform for reporting on access-to-medicines programs, in 2017. We did a descriptive analysis of the proportion of partners by sector, institution, and location. We used the Fischer’s exact test to analyze the relationship between the program strategies, disease focus, and countries with the type of program partners. Based on our empirical findings, we developed a typology of program partnerships, according to which we categorized each of the 63 programs.
Programs worked with three partners on average, the majority of which were local governmental or non-governmental organizations (70%). Most programs focused on health service strengthening (83%), community awareness and linkage to care (81%), and health service delivery (60%). Twenty-six of the 63 programs (41%) worked with the local Ministries of Health while 25 (40%) partnered with disease-specific organizations, 21 (33%) with hospitals, and 16 (25%) with academic institutions. Partnering with the Ministries of Health was significantly associated with the use of a health service strengthening program strategy (P = 0.02). Partnering with a hospital (P = 0.004) or private sector partner (P = 0.0009) was significantly associated with a program disease focus on cancer. Seventy-nine percent of the programs were solely funded by pharmaceutical companies. According to our program typology, 40 (63%) programs partnered directly or indirectly with multiple implementing organizations, which delivered the program directly to beneficiaries.
Pharmaceutical companies play a leading role in funding Access Accelerated programs with local governmental or non-governmental organizations mainly involved in program implementation. A detailed and transparent reporting of the role of local stakeholders in agenda setting, planning, and coordination of programs is needed to ensure public trust and accountability of programs led by pharmaceutical companies. More research is needed to identify the partnerships that are particularly suitable to promote efficient implementation, evaluation, and reporting depending on the nature of the program and context.
•Companies and partners take on different roles and responsibilities in biopharmaceutical industry-led access programs.•The program strategy is related to the type of partners involved.•Company-partner-beneficiary population relationships fall into four main types.</description><identifier>ISSN: 0033-3506</identifier><identifier>EISSN: 1476-5616</identifier><identifier>DOI: 10.1016/j.puhe.2019.12.008</identifier><identifier>PMID: 31958672</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Accelerated education ; Access ; Access Accelerated ; Access Observatory ; Access to medicines ; Accountability ; Beneficiaries ; Cancer ; Companies ; Content analysis ; Coordination ; Disease ; Drugs ; Empirical analysis ; Global health ; Global health partnerships ; Health services ; Hospitals ; Infectious diseases ; Local government ; NGOs ; Nongovernmental organizations ; Partnerships ; Pharmaceutical industry ; Pharmaceuticals ; Private sector ; Public-private partnerships ; Strengthening ; Typology</subject><ispartof>Public health (London), 2020-04, Vol.181, p.73-79</ispartof><rights>2019 The Royal Society for Public Health</rights><rights>Copyright © 2019 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Apr 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-77f401d5ac3254a2d1fadc8987ff8eade3f976d1f77457f970261f2ced91d9d23</citedby><cites>FETCH-LOGICAL-c384t-77f401d5ac3254a2d1fadc8987ff8eade3f976d1f77457f970261f2ced91d9d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0033350619304020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,30976,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31958672$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Umeh, C.A.</creatorcontrib><creatorcontrib>Rockers, P.C.</creatorcontrib><creatorcontrib>Laing, R.O.</creatorcontrib><creatorcontrib>Wagh, O.</creatorcontrib><creatorcontrib>Wirtz, V.J.</creatorcontrib><title>Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated</title><title>Public health (London)</title><addtitle>Public Health</addtitle><description>In spite of the increasing number of global health partnerships led by biopharmaceutical companies, there is a paucity of information on the number, type, and role of partners. This paper aims to analyze partnerships carrying out company programs included in Access Accelerated, a new industry initiative, focused on addressing the global non-communicable disease burden.
Document review and content analysis.
We extracted data on the number, type, and role of partners from 63 company programs reported into the Access Observatory, a public platform for reporting on access-to-medicines programs, in 2017. We did a descriptive analysis of the proportion of partners by sector, institution, and location. We used the Fischer’s exact test to analyze the relationship between the program strategies, disease focus, and countries with the type of program partners. Based on our empirical findings, we developed a typology of program partnerships, according to which we categorized each of the 63 programs.
Programs worked with three partners on average, the majority of which were local governmental or non-governmental organizations (70%). Most programs focused on health service strengthening (83%), community awareness and linkage to care (81%), and health service delivery (60%). Twenty-six of the 63 programs (41%) worked with the local Ministries of Health while 25 (40%) partnered with disease-specific organizations, 21 (33%) with hospitals, and 16 (25%) with academic institutions. Partnering with the Ministries of Health was significantly associated with the use of a health service strengthening program strategy (P = 0.02). Partnering with a hospital (P = 0.004) or private sector partner (P = 0.0009) was significantly associated with a program disease focus on cancer. Seventy-nine percent of the programs were solely funded by pharmaceutical companies. According to our program typology, 40 (63%) programs partnered directly or indirectly with multiple implementing organizations, which delivered the program directly to beneficiaries.
Pharmaceutical companies play a leading role in funding Access Accelerated programs with local governmental or non-governmental organizations mainly involved in program implementation. A detailed and transparent reporting of the role of local stakeholders in agenda setting, planning, and coordination of programs is needed to ensure public trust and accountability of programs led by pharmaceutical companies. More research is needed to identify the partnerships that are particularly suitable to promote efficient implementation, evaluation, and reporting depending on the nature of the program and context.
•Companies and partners take on different roles and responsibilities in biopharmaceutical industry-led access programs.•The program strategy is related to the type of partners involved.•Company-partner-beneficiary population relationships fall into four main types.</description><subject>Accelerated education</subject><subject>Access</subject><subject>Access Accelerated</subject><subject>Access Observatory</subject><subject>Access to medicines</subject><subject>Accountability</subject><subject>Beneficiaries</subject><subject>Cancer</subject><subject>Companies</subject><subject>Content analysis</subject><subject>Coordination</subject><subject>Disease</subject><subject>Drugs</subject><subject>Empirical analysis</subject><subject>Global health</subject><subject>Global health partnerships</subject><subject>Health services</subject><subject>Hospitals</subject><subject>Infectious diseases</subject><subject>Local government</subject><subject>NGOs</subject><subject>Nongovernmental organizations</subject><subject>Partnerships</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceuticals</subject><subject>Private sector</subject><subject>Public-private partnerships</subject><subject>Strengthening</subject><subject>Typology</subject><issn>0033-3506</issn><issn>1476-5616</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNp9kc1u1DAUhS1ERaeFF2CBLLFhk9Q_iZ0gNlUFBakSLGBteezrjkeJHey4qA_Rd66HKSxYsLrW1XeOju9B6DUlLSVUXOzbpeygZYSOLWUtIcMztKGdFE0vqHiONoRw3vCeiFN0lvOeEMIk71-gU07HfhCSbdDDt51OszZQVm_0hH2wJa_pvpnA4kWnNUDKO79k7KIpuS5jwNraBDn7cIvXHeDbKW6rdFuShYCjwyGGxsR5LqF6bifA1mfQGfJ7rHGCOw-_DtilMdXl95gg6RXsS3Ti9JTh1dM8Rz8-ffx-9bm5-Xr95erypjF86NZGStcRanttOOs7zSx12pphHKRzA2gL3I1S1K2UXS_rmzBBHTNgR2pHy_g5enf0XVL8WSCvava5pph0gFiyYrzjhEvKxoq-_Qfdx5JCTadYV1NQKntRKXakTIo5J3BqSX7W6V5Rog5lqb06lKUOZSnKVC2rit48WZftDPav5E87FfhwBKDeol4tqWw8hPoPn8Csykb_P_9HtrCoLQ</recordid><startdate>202004</startdate><enddate>202004</enddate><creator>Umeh, C.A.</creator><creator>Rockers, P.C.</creator><creator>Laing, R.O.</creator><creator>Wagh, O.</creator><creator>Wirtz, V.J.</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>202004</creationdate><title>Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated</title><author>Umeh, C.A. ; Rockers, P.C. ; Laing, R.O. ; Wagh, O. ; Wirtz, V.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-77f401d5ac3254a2d1fadc8987ff8eade3f976d1f77457f970261f2ced91d9d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Accelerated education</topic><topic>Access</topic><topic>Access Accelerated</topic><topic>Access Observatory</topic><topic>Access to medicines</topic><topic>Accountability</topic><topic>Beneficiaries</topic><topic>Cancer</topic><topic>Companies</topic><topic>Content analysis</topic><topic>Coordination</topic><topic>Disease</topic><topic>Drugs</topic><topic>Empirical analysis</topic><topic>Global health</topic><topic>Global health partnerships</topic><topic>Health services</topic><topic>Hospitals</topic><topic>Infectious diseases</topic><topic>Local government</topic><topic>NGOs</topic><topic>Nongovernmental organizations</topic><topic>Partnerships</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceuticals</topic><topic>Private sector</topic><topic>Public-private partnerships</topic><topic>Strengthening</topic><topic>Typology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Umeh, C.A.</creatorcontrib><creatorcontrib>Rockers, P.C.</creatorcontrib><creatorcontrib>Laing, R.O.</creatorcontrib><creatorcontrib>Wagh, O.</creatorcontrib><creatorcontrib>Wirtz, V.J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Public health (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Umeh, C.A.</au><au>Rockers, P.C.</au><au>Laing, R.O.</au><au>Wagh, O.</au><au>Wirtz, V.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated</atitle><jtitle>Public health (London)</jtitle><addtitle>Public Health</addtitle><date>2020-04</date><risdate>2020</risdate><volume>181</volume><spage>73</spage><epage>79</epage><pages>73-79</pages><issn>0033-3506</issn><eissn>1476-5616</eissn><abstract>In spite of the increasing number of global health partnerships led by biopharmaceutical companies, there is a paucity of information on the number, type, and role of partners. This paper aims to analyze partnerships carrying out company programs included in Access Accelerated, a new industry initiative, focused on addressing the global non-communicable disease burden.
Document review and content analysis.
We extracted data on the number, type, and role of partners from 63 company programs reported into the Access Observatory, a public platform for reporting on access-to-medicines programs, in 2017. We did a descriptive analysis of the proportion of partners by sector, institution, and location. We used the Fischer’s exact test to analyze the relationship between the program strategies, disease focus, and countries with the type of program partners. Based on our empirical findings, we developed a typology of program partnerships, according to which we categorized each of the 63 programs.
Programs worked with three partners on average, the majority of which were local governmental or non-governmental organizations (70%). Most programs focused on health service strengthening (83%), community awareness and linkage to care (81%), and health service delivery (60%). Twenty-six of the 63 programs (41%) worked with the local Ministries of Health while 25 (40%) partnered with disease-specific organizations, 21 (33%) with hospitals, and 16 (25%) with academic institutions. Partnering with the Ministries of Health was significantly associated with the use of a health service strengthening program strategy (P = 0.02). Partnering with a hospital (P = 0.004) or private sector partner (P = 0.0009) was significantly associated with a program disease focus on cancer. Seventy-nine percent of the programs were solely funded by pharmaceutical companies. According to our program typology, 40 (63%) programs partnered directly or indirectly with multiple implementing organizations, which delivered the program directly to beneficiaries.
Pharmaceutical companies play a leading role in funding Access Accelerated programs with local governmental or non-governmental organizations mainly involved in program implementation. A detailed and transparent reporting of the role of local stakeholders in agenda setting, planning, and coordination of programs is needed to ensure public trust and accountability of programs led by pharmaceutical companies. More research is needed to identify the partnerships that are particularly suitable to promote efficient implementation, evaluation, and reporting depending on the nature of the program and context.
•Companies and partners take on different roles and responsibilities in biopharmaceutical industry-led access programs.•The program strategy is related to the type of partners involved.•Company-partner-beneficiary population relationships fall into four main types.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>31958672</pmid><doi>10.1016/j.puhe.2019.12.008</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-3506 |
| ispartof | Public health (London), 2020-04, Vol.181, p.73-79 |
| issn | 0033-3506 1476-5616 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2343037129 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); Elsevier ScienceDirect Journals Collection |
| subjects | Accelerated education Access Access Accelerated Access Observatory Access to medicines Accountability Beneficiaries Cancer Companies Content analysis Coordination Disease Drugs Empirical analysis Global health Global health partnerships Health services Hospitals Infectious diseases Local government NGOs Nongovernmental organizations Partnerships Pharmaceutical industry Pharmaceuticals Private sector Public-private partnerships Strengthening Typology |
| title | Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T16%3A08%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmaceutical%20industry-led%20partnerships%20focused%20on%20addressing%20the%20global%20burden%20of%20non-communicable%20diseases:%20a%20review%20of%20Access%20Accelerated&rft.jtitle=Public%20health%20(London)&rft.au=Umeh,%20C.A.&rft.date=2020-04&rft.volume=181&rft.spage=73&rft.epage=79&rft.pages=73-79&rft.issn=0033-3506&rft.eissn=1476-5616&rft_id=info:doi/10.1016/j.puhe.2019.12.008&rft_dat=%3Cproquest_cross%3E2343037129%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2440111756&rft_id=info:pmid/31958672&rft_els_id=S0033350619304020&rfr_iscdi=true |